ClinicalTrials.gg
RecruitingNCT05446883Updated Nov 30, 2022

QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

A Phase 3 interventional study of QL1706 and Placebo in METASTATIC CERVICAL CANCER, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 3 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-30.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
498
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing Iparomlimab/Tuvonralimab in Uterine Cervical Neoplasms — 9 open to participants now, 10 under way, 1 of them phase 3. Iparomlimab/Tuvonralimab · Uterine Cervical Neoplasms.

Planned enrollment
Largest of 12
498 · median 50
Started
2022
the only one that year
Phase 3
Only one
of the 12
Registered
2nd of 12
by date
Lead sponsor
3 of 12
Qilu Pharmaceutical Co., Ltd.

Among the 12 studies testing Iparomlimab/Tuvonralimab in Uterine Cervical Neoplasms, this one has the largest planned enrollment, is the only one that started in 2022, is the only one in phase 3, and was the 2nd registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

9 of the 12 studies testing Iparomlimab/Tuvonralimab in Uterine Cervical Neoplasms are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About Iparomlimab/Tuvonralimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Iparomlimab/Tuvonralimab in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study in 498 patients with persistent, recurrent or metastatic cervical cancer.Experimental: QL1706 + Chemotherapy (Paclitaxel-cisplatin/Carboplatin) ± Bevacizumab; Control group: placebo + chemotherapy (paclitaxel-cisplatin/carboplatin) ± bevacizumab

Read the detailed description

Subjects must provide sufficient archival or newly obtained tumor tissue samples to determine PD-L1 expression level to be eligible for screening.During the screening phase, eligible subjects will be stratified by use of bevacizumab (yes vs no), prior concurrent chemoradiation therapy (yes vs no), and PD- L1 level (CPS \< 1 vs 1 ≤ CPS \< 10 vs CPS ≥ 10) and randomized 1:1 into the experimental or control arm.Experimental: QL1706 + Chemotherapy (Paclitaxel-cisplatin/Carboplatin) ± Bevacizumab;Control group: placebo + chemotherapy (paclitaxel-cisplatin/carboplatin) ± bevacizumab

03

Conditions studied

  • METASTATIC CERVICAL CANCER
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject fully understood and voluntarily signed the form.
  • confirmed cervical cancer.
  • At least one measurable tumor lesion by CT or MRI according to 1.1 criteria.
  • All subjects must provide archived or freshly obtained tumor tissue samples, approximately 7 (minimum of 5) unstained FFPE pathology slides (preferably newly obtained tumor tissue samples) within 5 years prior to randomization.
  • (ECOG) performance status of 0 or 1.
  • Expected survival ≥ 12 weeks.
  • Adequate level of vital organ function

Exclusion criteria

Exclusion Criteria:

  • Previously received immunotherapy, including immune checkpoint inhibitory antibodies (such as: , PD-L1, CTLA-4 antibodies, etc.), immune checkpoint agonistic antibodies (such as: anti-ICOS, 0, CD137, GITR, OX40 antibodies, etc.), and immune cell therapy; previously received VEGF/VEGFR inhibitors, such as bevacizumab, ramucirumab, abercept and tyrosine kinase inhibitors.
  • Systemic infection or other serious infection requiring intravenous antibiotics for 7 days before randomization, or unexplained fever > 38.5℃ during screening or before enrollment (except fever caused by tumor, as judged by the investigator)
  • Within two weeks before randomization, there is a need for systemic use of (> 10 mg daily prednisone or equivalent) or other drugs (such as cyclophosphamide, azathioprine, methotrexate, thalidomide, TNF-α inhibitors, etc.) treatment of the disease; Topical corticosteroids, nasal sprays, and inhaled steroids are allowed. Systemic corticosteroids are permitted for the prevention of contrast allergy。
  • Systemic treatment with immunomodulatory drugs (such as thymosin, lentinan, interferon, interleukin, etc.) within two weeks before randomization
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
498 participants (estimated)

Study arms

  • Experimental
    QL1706+chemotherapy± bevacizumab

    QL1706 (5 mg/kg) + paclitaxel (175 mg/m2) + cisplatin (50 mg/m2)/carboplatin (AUC 5) ± bevacizumab (15 mg/kg)

    Drug: QL1706 · Drug: Paclitaxel injection · Drug: Cisplatin/Carboplatin

  • Placebo comparator
    Placebo+chemotherapy± bevacizumab

    Placebo + paclitaxel (175 mg/m2) + cisplatin (50 mg/m2)/carboplatin (AUC 5) ± bevacizumab (15 mg/kg)

    Drug: Placebo · Drug: Paclitaxel injection · Drug: Cisplatin/Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. PFS by BICR based on RECIST v1.1

    PFS by BICR based on RECIST v1.1

    Time frame: Informed consent until disease progression or death, which ever occurs first (up to approximately 24 months)

  2. OS

    OS

    Time frame: From date of randomization until the date of death from any cause, whichever came first, assessed up to 2 years

Secondary outcomes

  1. PFS and 12-month PFS rate assessed by investigator based on RECIST v1.1 criteria

    PFS and 12-month PFS rate assessed by investigator based on RECIST v1.1 criteria

    Time frame: Informed consent until disease progression or death, which ever occurs first (up to approximately 24 months

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Involves subject privacy and does not intend to share

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Sep 2024, 23 months after the start.

Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's planned 23 months is below that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2022
First posted
Jul 7, 2022
StartActual
Sep 23, 2022
Primary completionEst.
Sep 1, 2024
CompletionEst.
Jul 1, 2025
Last update
Nov 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05446883
Responsible party
Sponsor
First posted
Jul 7, 2022
Start date
Sep 23, 2022
Primary completion
Sep 1, 2024 (estimated)
Completion
Jul 1, 2025 (estimated)
Last update
Nov 30, 2022

Study contacts

Xiaoli Zhang
Contact
xiaoli3.zhang@qilu-pharma.com
008610-50813552

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iparomlimab/Tuvonralimab

Start the discussion